Streetbeat News

Analyst Ratings

TARS

Oppenheimer analyst Francois Brisebois has reiterated an Outperform rating on Tarsus Pharmaceuticals (NASDAQ:TARS) and increased the price target from $55 to $59.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 12:48 pm

APLS

Wedbush analyst Laura Chico maintains a Neutral rating on Apellis Pharmaceuticals (NASDAQ:APLS) and raises the price target from $60 to $67.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 12:48 pm

RSG

Oppenheimer analyst Noah Kaye maintains an Outperform rating on Republic Services (NYSE:RSG) and raises the price target from $182 to $195.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 12:46 pm

QUIK

Oppenheimer analyst Martin Yang has reiterated an Outperform rating on QuickLogic (NASDAQ:QUIK) and increased the price target from $12 to $16.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 12:44 pm

IAS

Oppenheimer analyst Jason Helfstein maintains an Outperform rating on Integral Ad Science (IAS) but lowers the price target from $25 to $20.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 12:42 pm

FSLR

Oppenheimer analyst Colin Rusch maintains an Outperform rating on First Solar (NASDAQ:FSLR) and raises the price target from $268 to $269.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 12:40 pm

ARQT

Needham analyst Serge Belanger has maintained a Buy rating on Arcutis Biotherapeutics (NASDAQ:ARQT) and doubled the price target from $8 to $16.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 12:39 pm

COMP

Oppenheimer analyst Jason Helfstein has reiterated an Outperform rating on Compass (NYSE:COMP) and raised the price target from $5.5 to $6.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 12:38 pm

DV

Needham analyst Laura Martin reiterates a Buy rating on DoubleVerify Holdings (DV) with a maintained price target of $45.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 12:37 pm

CLVT

Oppenheimer analyst Owen Lau maintains an Outperform rating on Clarivate (NYSE:CLVT) but lowers the price target from $11 to $10.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 12:36 pm